BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate
October 25, 2023 09:15 ET
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology
October 20, 2023 09:15 ET
|
BriaCell Therapeutics Corp.
According to American Cancer Society Facts and Figures, breast cancer is the most common cancer in the United States with 300,590 expected new cases in 202343,700 women and men are expected to die of...
BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences
October 18, 2023 09:00 ET
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic
October 11, 2023 09:10 ET
|
BriaCell Therapeutics Corp.
Dr. Adam M. Brufsky of University of Pittsburgh School of Medicine and Dr. Saranya Chumsri of Mayo Clinic will discuss the current treatment landscape for patients with advanced metastatic breast...
BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer
October 04, 2023 09:00 ET
|
BriaCell Therapeutics Corp.
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer
October 03, 2023 09:00 ET
|
BriaCell Therapeutics Corp.
The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or physician’s choice therapy (1:1)Positive results of the pivotal Phase 3 study...
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer
September 08, 2023 07:00 ET
|
BriaCell Therapeutics Corp.
Median overall survival of 13.5 months in BriaCell’s advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature)21 out of 29 patients treated since...
BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders
August 31, 2023 11:54 ET
|
BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. closes Arrangement effecting the distribution described in the plan of arrangement. TORONTO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX,...
BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT™ in High-Risk Early-Stage Triple Negative Breast Cancer
August 31, 2023 08:21 ET
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing Shareholders
August 25, 2023 14:33 ET
|
BriaCell Therapeutics Corp.
August 31, 2023 is the expected effective date for the distribution contemplated by the Arrangement. PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell...